Heterogeneity in RAS mutations: One size does not fit all.

Abstract excerpt

Although oncogenic driver mutations in RAS occur in 20% of cancers, heterogeneity in the biologic outputs of different RAS mutants has hampered efforts to develop effective treatments for RAS-mutated cancers. In this issue of Science Signaling, Huynh et al. show that even among KRASQ61 mutants, the specific amino acid that is substituted substantially affects mutant KRAS biologic activity and oncogenicity.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biological Products
• Share to Mutation
• Share to Neoplasms